Yarrow Bioscience, Inc.
YARW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001566044
No open-market purchases or sales by Yarrow Bioscience, Inc. insiders were filed in the last 90 days; 46 institutions reported holding it in 13F filings for Q2 2026, worth $8.79M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Yarrow Bioscience, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- +3 vs. Q4 2024
- Shares held
- 7.16M
- +97.0K (+1.4%) vs. Q4 2024
- Total value
- $11.5M
- −$12.0M (−51.0%) vs. Q4 2024
- New holders
- 7
- 15 more added
- Sold out
- 4
- 7 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting YARW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 46 | $8.79M |
| Q1 2026 | 46 | $8.49M |
| Q4 2025 | 45 | $5.35M |
| Q3 2025 | 36 | $1.33M |
| Q2 2025 | 46 | $13.4M |
| Q1 2025 | 38 | $11.5M |
| Q4 2024 | 35 | $23.4M |
| Q3 2024 | 33 | $14.3M |
| Q2 2024 | 32 | $16.1M |
| Q1 2024 | 32 | $22.9M |
| Q4 2023 | 33 | $18.4M |
| Q3 2023 | 21 | $1.54M |
| Q2 2023 | 20 | $1.63M |
| Q1 2023 | 23 | $1.10M |
| Q4 2022 | 41 | $1.10M |
| Q3 2022 | 41 | $1.84M |
| Q2 2022 | 41 | $3.25M |
| Q1 2022 | 45 | $5.63M |
| Q4 2021 | 55 | $12.5M |
| Q3 2021 | 65 | $20.1M |
| Q2 2021 | 73 | $64.0M |
| Q1 2021 | 87 | $152.4M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Yarrow Bioscience, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Eventide Asset Management, LLC | 1,394,336 | $2.37M | 0.05% | 00.0% | Unchanged |
| Citadel Advisors LLC | 1,100,329 | $1.74M | 0.00% | −130,128−10.6% | Reduced |
| Acorn Capital Advisors, LLC | 785,938 | $1.24M | 0.83% | +328,968+72.0% | Added |
| DAFNA Capital Management LLC | 636,103 | $1.01M | 0.28% | +636,103 | New |
| Vanguard Group Inc | 475,650 | $751.5K | 0.00% | +521+0.1% | Added |
| Exome Asset Management LLC | 462,801 | $731.2K | 0.65% | +109,367+30.9% | Added |
| Palo Alto Investors LP | 445,434 | $703.8K | 0.13% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 344,134 | $543.7K | 0.00% | +190,000+123.3% | Added |
| Patient Square Capital LP | 257,033 | $406.1K | 0.17% | +257,033 | New |
| Parkman Healthcare Partners LLC | 217,978 | $344.4K | 0.04% | +65,005+42.5% | Added |
| Prelude Capital Management, LLC | 141,502 | $223.6K | 0.02% | +82,102+138.2% | Added |
| Geode Capital Management, LLC | 133,490 | $210.9K | 0.00% | −1,527−1.1% | Reduced |
| Renaissance Technologies LLC | 115,143 | $181.9K | 0.00% | +90,200+361.6% | Added |
| Schonfeld Strategic Advisors LLC | 84,978 | $134.3K | 0.00% | −91,680−51.9% | Reduced |
| BlackRock, Inc. | 82,579 | $130.5K | 0.00% | −735−0.9% | Reduced |
| ADAR1 Capital Management, LLC | 70,419 | $111.3K | 0.02% | +70,419 | New |
| Susquehanna International Group, LLP | 57,762 | $91.3K | 0.00% | −13,070−18.5% | Reduced |
| Bridgeway Capital Management, LLC | 51,958 | $82.1K | 0.00% | +15,000+40.6% | Added |
| Staley Capital Advisers Inc | 51,472 | $81.3K | 0.00% | +15,000+41.1% | Added |
| UBS Oconnor LLC | 45,557 | $72.0K | 0.00% | −200,243−81.5% | Reduced |
| XTX Topco Ltd | 33,052 | $52.2K | 0.00% | +12,034+57.3% | Added |
| HRT Financial LP | 26,242 | $41.0K | 0.00% | +26,242 | New |
| Northern Trust Corp | 23,971 | $37.9K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 19,574 | $31.0K | 0.00% | +19,574 | New |
| Commonwealth Equity Services, LLC | 18,298 | $29.0K | 0.00% | 00.0% | Unchanged |
| Shay Capital LLC | 18,015 | $28.5K | 0.01% | +18,015 | New |
| Bank of America Corp | 17,163 | $27.1K | 0.00% | +15,672+1,051.1% | Added |
| State Street Corp | 15,765 | $24.9K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 12,811 | $20.2K | 0.00% | +8,512+198.0% | Added |
| UBS Group AG | 7,576 | $12.0K | 0.00% | +6,945+1,100.6% | Added |
| JPMorgan Chase & Co | 5,981 | $9.45K | 0.00% | +5,667+1,804.8% | Added |
| Tower Research Capital LLC (TRC) | 4,296 | $6.79K | 0.00% | +2,910+210.0% | Added |
| Royal Bank of Canada | 2,440 | $4.00K | 0.00% | −22,789−90.3% | Reduced |
| MB, Levis & Associates, LLC | 1,041 | $1.65K | 0.00% | 00.0% | Unchanged |
| CWM, LLC | 500 | $1.00K | 0.00% | 00.0% | Unchanged |
| Centerpoint Advisors, LLC | 350 | $1.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 65 | $103 | 0.00% | 00.0% | Unchanged |
| Truvestments Capital LLC | 25 | $40 | 0.00% | +25 | New |
| Cormorant Asset Management, LP | 0 | $0 | 0.00% | −1,394,336−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −20,286−100.0% | Sold out |
| BFSG, LLC | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |